Best Niche Antibody-based Biologics

Therapeutics R&D FAQ

What is the focus area of AB Bioscience R&D for therapeutics?

AB Biosciences’ R&D for protein therapeutics focuses on engineering multi-valent protein biologics that are highly efficacious for interacting with disease targets.

What is your core technology for engineering the multi-valent biologics?

We interrogate abundant protein scaffolds and protein models to find best match with effector proteins interacting with specific disease targets. For example, a scaffold fused with the extracellular domain of PD-1 is an active program for engineering a Keytruda-competing protein biologics.

Can you disclose the leading program based on this scaffold platform technology?

PRIM-II (Pan Receptor Interacting Molecule 2nd Generation) is a non-collagen-based trimeric immunoglobulin Fc protein capable of masking Fcg receptors including the neonatal receptor (FcRn) with high avidity. PRIM-II is being developed for treatment of autoimmune disorders such as CIDP (chronic inflammatory demyelinating poly neuropathy), myasthenia gravis, GBS (Guillain-Barré syndrome) and Kawasaki disease.

What are the therapeutic candidates in your pipeline?

In addition to the PD-1 decoy mentioned above, we are actively working on scaffold-based competing biologics as the next generation therapeutics of approved antibodies, other receptor decoys and multivalence vaccine for influenza and HIV.

For any other questions, email us at or call (617) 208-8549